In a long‐term follow‐up subclinical trial known as CLARICOR43 (effect of clarithromycin versus placebo on mortality and morbidity in patients with ischaemic heart disease), serum CTSB levels were assessed in 4372 stable coronary heart disease patients. The gene discussed is CTSB; the disease is coronary artery disorder.